NCT00100906View on ClinicalTrials.gov

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2013

Conditions
Kidney Cancer
Interventions
DRUG

IL-2

Immunotherapy with interleukin-2

DRUG

ATRA

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Chiron Corporation
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Chiron Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER